Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing.
Evans, D Gareth R Lalloo, Fiona Cramer, A Jones, E Knox, F Amir, E Howell, Anthony
Evans, D Gareth R
Lalloo, Fiona
Cramer, A
Jones, E
Knox, F
Amir, E
Howell, Anthony
Citations
Altmetric:
Abstract
Selection for genetic testing of BRCA1/BRCA2 is an important area of healthcare. Although testing costs for mutational analysis are falling, costs in North America remain in excess of US$3000 (UK price can be 690 pounds). Guidelines in most countries use a 10-20% threshold of detecting a mutation in BRCA1/2 combined within a family before mutational analysis is considered. A number of computer-based models have been developed. However, use of these models can be time consuming and difficult. The Manchester scoring system was developed in 2003 to simplify the selection process without losing accuracy.
Description
Date
2009-12
Publisher
Collections
Keywords
Breast Cancer
Biological Tumour Markers
Biological Tumour Markers
Type
Article
Citation
Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing. 2009, 46 (12):811-7 J Med Genet